This page contains a Flash digital edition of a book.
28 chromatography • spectroscopy


Sensitivity and robustness top mass spec market demands


Laboratories are looking for ever greater sensitivity and robustness from their mass spec technologies – and the vendors are responding. Sean Ottewell reports.


Les laboratoires attendent de leurs technologies de spectrométrie de masse une sensibilité et une robustesse toujours plus élevées et les fournisseurs y réagissent. Un article de Sean Ottewell.


Labors verlangen von ihren speziellen Massentechnologien eine immer größere Empfindlichkeit und Strapazierfähigkeit – und die Anbieter reagieren entsprechend. Sean Ottewell berichtet.


B


ruker’s new aurora Elite is an ultra-sensitive inductively coupled plasma mass


spectrometer (ICP-MS) designed to complement the workhorse aurora M90 ICP-MS for routine laboratory analysis.


“Te new aurora Elite sets unprecedented and truly exceptional standards for sensitivity and matrix robustness, even exceeding the performance of expensive magnetic sector field ICP-MS systems in many aspects, and far exceeding the sensitivity of all other quadrupole ICP-MS systems on the market today,” says the company.


Te new device boasts a host of performance enhancements and new features, with unprecedented 1.5 gigahertz per parts per million (1.5 GHz/ppm) sensitivity for precise and


accurate quantification at single digit ppt levels and below, which, says Bruker, makes the aurora Elite the most sensitive ICP-MS instrument on the market.


Such sensitivity makes it eminently suitable for the semiconductor, geochemistry, materials science and related applications.


Te lowest oxide ratios using its patented turner-interlaced coils ensures robust plasma conditions for complete matrix decomposition, all without the requirement of a plasma shield or guard electrode.


Te combination of the aurora


Elite’s high sensitivity with the all-digital detector delivers excellent results for isotope ratio determinations of low concentrations and for large ratios,


and this is true for liquids and solids.


Te combination of GHz sensitivity with very short integration times makes this an ideal instrument for the analysis of nanoparticles at the smallest dimensions (Fig. 1). Te incorporation of an easy- to-use collision reaction interface (CRI II) provides a solution for simple, robust, maintenance-free interference challenges, with the convenience of either helium- or hydrogen mode, for improved detection limits of spectrally interfered isotopes and highest accuracy.


Te expanded ICP-MS range from Bruker, including the enhanced aurora M90 and the new aurora Elite, now also offers 21 CFR Part 11 compliance to meet the requirements of pharmaceutical, biotech and contract research organisation customers.


Biomarker collaboration Agilent Technologies and Applied Proteomics have agreed to collaborate on highly multiplexed protein assays and workflow solutions for multiple reaction monitoring through mass spectrometry.


Proteins perform many important cellular functions, are the targets of most drugs and therapies, and are often used as biomarkers for detecting and monitoring disease.


Fig. 1. The combination of the aurora Elite’s GHz sensitivity with very short integration times makes this an ideal instrument for the analysis of nanoparticles at the smallest dimensions.


www.scientistlive.com


Applied Proteomics will leverage Agilent 6490 Triple Quadrupole LC/MS, 1290 Infinity LC, RapidFire 360 MS system and Bravo liquid-handling technologies to optimise the throughput of highly multiplexed proteomic assays.


Multiple reaction monitoring, a


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52